Clinical Trial: Clinical Trial to Evaluate the Tolerance of TQB2210 Injection
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Advanced Malignant Tumours
Study Type: INTERVENTIONAL
Official Title: Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors
Brief Summary:
TQB2210 injection is a humanized monoclonal antibody against FGFR2b, which can bind to FGFR2b with high specificity and inhibit tumor growth by blocking the signaling pathway mediated by fibroblast growth factor receptor.The aim of this experiment is to evaluate the tolerability, pharmacokinetics, and preliminary efficacy of TQB2210 injection in patients with advanced malignant tumors, and to assess its effectiveness and phase II recommended dose (RP2D) in advanced malignant tumors with FGFR2b overexpression, such…
Read more